



ACCESSUS HEALTH

A brand of **ECKER**  **ECKER**

In close collaboration
with EconMed -
Partner in the Project:



European HTA database

Europe-wide HTA database – your central starting point for preparation for EU HTA and European market access

Early launch Q1 2025!
Contact us for early
Access options!

Europe-wide coverage of country-specific HTA information


The Accessus network's European HTA database is a comprehensive, Europe-wide database of HTA procedures to support preparation for EU HTA assessments and all European and local market access activities. With data curated by local experts, it provides a reliable, up-to-date overview of relevant HTA and P&R documents, as available for each European country – your ideal starting point for PICO scoping.

Scope

- Document database for HTA procedures from all key European markets
- Both national and EU HTA procedures
- Documents on clinical evidence assessment and P&R (e.g., benefit assessment resolutions, comparative therapy information, reimbursement recommendations/decisions)"
- For all products authorized via centralized procedure (EMA)
- Up-to-date: monthly updates for coverage of the latest procedures

Local expertise, common methodology

This central idea of the Accessus Health network also applies to the European HTA database: The data are curated by local network partners possessing country-specific HTA expertise, following one common methodology, in order to provide you with reliable, comprehensive HTA information across Europe.



Versatile search functionality to answer your specific questions

With its intuitive, flexible options for conducting, filtering, and displaying database searches, the Accessus network's European HTA database can quickly provide you with information tailored to your individual needs – ranging from high-level searches for available HTA procedures across Europe to complex searches to systematically answer detailed questions.

The search interface includes a main search bar with a 'Clear search' button. Below it are three rows of search criteria, each with an 'AND' or 'OR' operator, a search term input, and a 'Select field (optional)' dropdown. Further down are filters for 'Procedure', 'Language', 'Procedure for', 'Regulatory', 'Start year' (1990 to 2024), and 'End year'. A 'Search' button is located at the bottom right.

Key functionalities of the database application


- As a web application, the Accessus network's European HTA database is easily accessible from anywhere and anytime via your personal subscription – no installation required.
- Both simple and complex searches can be rapidly conducted via the easy-to-use user interface, to quickly find HTA procedures and access the documents matching your questions.
- For specificity, a variety of search filters and results filters enables targeted searches for HTA documents by, e.g., active substance, therapeutic area, country, time period, document type, and many more.
- For maximum sensitivity, full-text searches of all included HTA documents are possible.
- Different views of the search results providing different granularity can be chosen to best match your specific queries – from high-level graphical or tabular overviews to detailed lists.
- Comprehensive information on the country-specific scope of the database as well as a technical user guide are directly integrated into the application.
- **Stay up-to-date with customized alerts:** set alerts for specific search queries to be notified automatically once new relevant HTA procedures become available.

Search results

Displaying filtered search results: 8 HTA procedures, 27 documents

Year	Procedure for	Language	Procedure	Active substance	Trade name	Marketing authorization holder	Therapeutic Area (MeSH)
2023	Spain	ES	Clinical Evidence Assessment	ciltacabtagene autoleucel	Carvykti	Janssen-Cilag International NV	Multiple Myeloma
Documents for this procedure matching your query							
IP1: Carvykti (Ciltacabtagene autoleucel) - Multiple myeloma				04A01	Clinical Evidence Assessment	16.10.2023	ES
CIPM resolution: Carvykti (Ciltacabtagene autoleucel) - Multiple myeloma				04B01	Pricing & Reimbursement	29.01.2024	ES
2023	Germany	DE, EN	Clinical Evidence Assessment	ciltacabtagene autoleucel	Carvykti	Janssen-Cilag International NV	Multiple Myeloma
2024	Germany	DE	Clinical Evidence Assessment	ciltacabtagene autoleucel	Carvykti	Janssen-Cilag International NV	Multiple Myeloma
Documents for this procedure matching your query							
Beschluss: Carvykti (Ciltacabtagen autoleucel) - Multiples Myelom				01A01	Clinical Evidence Assessment	18.07.2024	DE
Tragende Gründe zum Beschluss: Carvykti (Ciltacabtagen autoleucel) - Multiples Myelom				01A02	Clinical Evidence Assessment	18.07.2024	DE
2022	France	FR	Clinical Evidence Assessment	ciltacabtagene autoleucel	Carvykti	Janssen-Cilag International NV	
Documents for this procedure matching your query							
CARVYKTI_23112022_AVIS_CT19858				02A01	Clinical Evidence Assessment	01.12.2022	FR
CARVYKTI DECISION ET AVIS CT				02A03	Clinical Evidence Assessment	25.09.2023	FR

Filter results





Accessus Health offers Market Access services for all European markets. 250 local Market Access experts from our network of partner companies follow one common methodology.

#ToBeYourGatewayToEurope

Your contacts:

Janine Leismann
CEO
j.leismann@accessus-health.eu
Phone: +49 40 4133081-26
www.accessus-health.eu

Dr. Florentin Köhnemann
CEO
f.koehnemann@accessus-health.eu
Phone: +49 40 4133081-48
www.accessus-health.eu